767 related articles for article (PubMed ID: 25423276)
1. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
6. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
7. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
8. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
9. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
10. Pathology of acromegaly.
Horvath E; Kovacs K
Neuroendocrinology; 2006; 83(3-4):161-5. PubMed ID: 17047379
[TBL] [Abstract][Full Text] [Related]
11. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic Transsphenoidal Approach for Acromegaly with Remission Rates in 401 Patients: 2010 Consensus Criteria.
Anik I; Cabuk B; Gokbel A; Selek A; Cetinarslan B; Anik Y; Ceylan S
World Neurosurg; 2017 Dec; 108():278-290. PubMed ID: 28887283
[TBL] [Abstract][Full Text] [Related]
13. Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study.
Schaller B
Pituitary; 2002; 5(4):247-53. PubMed ID: 14558673
[TBL] [Abstract][Full Text] [Related]
14. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control.
Tirosh A; Papadakis GZ; Chittiboina P; Lyssikatos C; Belyavskaya E; Keil M; Lodish MB; Stratakis CA
Horm Metab Res; 2017 Jun; 49(6):440-445. PubMed ID: 28472827
[TBL] [Abstract][Full Text] [Related]
15. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays.
Sarkar S; Jacob KS; Pratheesh R; Chacko AG
Acta Neurochir (Wien); 2014 Jul; 156(7):1379-87; discussion 1387. PubMed ID: 24781680
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
17. Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.
Koylu B; Firlatan B; Sendur SN; Oguz SH; Dagdelen S; Erbas T
Endocrine; 2023 Mar; 79(3):545-553. PubMed ID: 36318446
[TBL] [Abstract][Full Text] [Related]
18. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
19. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J; Vance ML; Lopes MB; Laws ER
J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
[TBL] [Abstract][Full Text] [Related]
20. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly.
Sarkar S; Chacko AG; Chacko G
Acta Neurochir (Wien); 2014 Dec; 156(12):2221-30; discussion 2230. PubMed ID: 25238988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]